Today: 10 June 2026
GE Vernova stock flat after-hours as year-end trading thins; what investors watch next for GEV
30 December 2025
2 mins read

GE Vernova stock flat after-hours as year-end trading thins; what investors watch next for GEV

NEW YORK, December 29, 2025, 6:16 PM ET — After-hours

  • GE Vernova shares ended essentially flat at $663.46 in regular trading; after-hours action was muted.
  • Wall Street slipped in light year-end volume as tech stocks pulled back.
  • Focus is shifting to early-2026 results and execution against GE Vernova’s raised 2026 targets.

GE Vernova Inc shares were little changed in after-hours trading on Monday after finishing the regular session essentially flat, even as U.S. stocks ended lower to start the final week of 2025.

The pause matters because GE Vernova has become one of the market’s most closely watched “power buildout” names, and year-end sessions often amplify positioning as fund managers lock in gains or rebalance.

Investors have bid up power and grid suppliers on expectations that electricity demand from data centers will keep climbing, leaving the stock sensitive to any new signal on orders, margins and cash generation.

GE Vernova ended the regular session at $663.46. The stock traded between $651.77 and $670.99, with about 2.1 million shares changing hands, according to market data.

The broader tape was softer. The S&P 500 fell 0.35% and the Nasdaq dropped 0.50% as heavyweight technology names retreated, Reuters reported, in what it described as light holiday trading.

The company’s most recent catalyst came earlier this month. At a Dec. 9 investor update, GE Vernova forecast 2026 revenue of $41 billion to $42 billion and free cash flow of $4.5 billion to $5.0 billion, up from its 2025 targets; free cash flow is cash left after capital spending. It also projected 16% to 18% organic growth in its power segment and 20% in electrification, with organic growth excluding currency swings and acquisitions, and it lifted its share repurchase authorization to $10 billion while doubling its quarterly dividend to 50 cents a share.

GE Vernova’s improved outlook followed similar momentum across the gas turbine supply chain. Rivals Siemens Energy and Mitsubishi Heavy Industries have also raised targets, Reuters reported, underscoring the competitive rush to meet demand for large power equipment.

Even after Monday’s flat close, the stock is up about 102% year-to-date and sits about 9% below its 52-week high of $731, giving the company a market value of roughly $180 billion, according to market data compiled by Finviz.

Supply-chain risks remain on watch. GE Vernova Chief Executive Scott Strazik said the company is working with the U.S. government to build stockpiles of yttrium, a rare-earth element used in high-temperature coatings and alloys in gas turbines. “We are very focused on it every day,” Strazik said. Reuters

For traders, Monday’s intraday swing — a dip into the low $650s followed by a rebound — highlighted how quickly sentiment can shift around year-end, particularly in stocks that have run hard.

The next clear catalyst is the company’s fourth-quarter results. GE Vernova has not confirmed the reporting date, but MarketBeat lists an estimated earnings date of Jan. 28, 2026 based on prior reporting patterns.

Before that, investors will be looking for updates on orders, margins and cash returns as the company moves from guidance to delivery. GE Vernova has said its increased dividend is payable on Feb. 2, 2026 to shareholders of record on Jan. 5, a near-term marker for income-focused holders.

Stock Market Today

  • MindWalk Launches ReefIQ for Enhanced AI-Driven Drug Discovery
    June 10, 2026, 9:49 AM EDT. MindWalk Holdings Corp. (NASDAQ: HYFT) introduced ReefIQ™, a biological context layer designed to unify fragmented drug discovery data for AI analysis. The technology integrates diverse biological information such as sequences, structures, and assay results into a governed, queryable network. This enables MindWalk's LensAI tool and client-selected models to perform more accurate hypothesis generation and target discovery. By preserving data provenance and program history, ReefIQ aims to enhance trust and efficiency in regulated drug development environments. CEO Dr. Jennifer Bath emphasized that ReefIQ closes the data gaps in biological context, crucial for reliable AI-driven insights in life sciences.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Next Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Go toTop